Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Analyst Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AXSM Stock 12 Month Forecast
Average Price Target
$196.82
▲(17.47% Upside)
| Highest Price Target$248.00 | Average Price Target$196.82 | Lowest Price Target$148.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Needham
$225
Buy
34.29%
Upside
Reiterated
01/12/26
William Blair
Buy
―
Reiterated
01/12/26
We remain confident as the company continues to execute on the commercial front and on its clinically de-risked pipeline. Axsome also recently announced sNDA acceptance and granting of priority review for Auvelity in Alzheimer’s disease agitation (AD-A), with a PDUFA date of April 30, 2026. We view the granting of priority review as a win for Axsome shares, supportive of the unmet need in the indication and the approvability of the data package (see our note: FDA Accepts sNDA for 2026 PDUFA and Supportive of Unmet Need). We attribute an 85% likelihood of approval for Auvelity in AD-A, which we see as a large revenue opportunity with peak sales of over $2 billion and meaningful commercial expansion beyond major depressive disorder (MDD) alone.
Mizuho Securities
$217
Buy
29.51%
Upside
Reiterated
01/09/26
Morgan Stanley
$196→$204
Hold
21.75%
Upside
Downgraded
01/08/26
UBS
$163→$248
Buy
48.02%
Upside
Reiterated
01/06/26
H.C. Wainwright
$185→$200
Buy
19.37%
Upside
Reiterated
01/05/26
Truist Financial
Buy
―
Reiterated
01/02/26
Wells Fargo
$157
Buy
-6.30%
Downside
Reiterated
12/17/25
RBC Capital
$198
Buy
18.17%
Upside
Reiterated
12/12/25
Bank of America Securities
$178
Buy
6.24%
Upside
Reiterated
12/08/25
Piper Sandler
$148
Buy
-11.67%
Downside
Reiterated
12/05/25
Leerink Partners
Buy
―
Reiterated
10/07/25
B. Riley Securities
$179
Buy
6.83%
Upside
Initiated
10/01/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
$225
Buy
34.29%
Upside
Reiterated
01/12/26
William Blair
Buy
―
Reiterated
01/12/26
We remain confident as the company continues to execute on the commercial front and on its clinically de-risked pipeline. Axsome also recently announced sNDA acceptance and granting of priority review for Auvelity in Alzheimer’s disease agitation (AD-A), with a PDUFA date of April 30, 2026. We view the granting of priority review as a win for Axsome shares, supportive of the unmet need in the indication and the approvability of the data package (see our note: FDA Accepts sNDA for 2026 PDUFA and Supportive of Unmet Need). We attribute an 85% likelihood of approval for Auvelity in AD-A, which we see as a large revenue opportunity with peak sales of over $2 billion and meaningful commercial expansion beyond major depressive disorder (MDD) alone.
Mizuho Securities
$217
Buy
29.51%
Upside
Reiterated
01/09/26
Morgan Stanley
$196→$204
Hold
21.75%
Upside
Downgraded
01/08/26
UBS
$163→$248
Buy
48.02%
Upside
Reiterated
01/06/26
H.C. Wainwright
$185→$200
Buy
19.37%
Upside
Reiterated
01/05/26
Truist Financial
Buy
―
Reiterated
01/02/26
Wells Fargo
$157
Buy
-6.30%
Downside
Reiterated
12/17/25
RBC Capital
$198
Buy
18.17%
Upside
Reiterated
12/12/25
Bank of America Securities
$178
Buy
6.24%
Upside
Reiterated
12/08/25
Piper Sandler
$148
Buy
-11.67%
Downside
Reiterated
12/05/25
Leerink Partners
Buy
―
Reiterated
10/07/25
B. Riley Securities
$179
Buy
6.83%
Upside
Initiated
10/01/25
Best Analysts Covering Axsome Therapeutics
3 Months
xxx
Success Rate
18/26 ratings generated profit
Average Return
+13.70%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +13.70% per trade.
1 Year
Success Rate
22/22 ratings generated profit
Average Return
+43.91%
reiterated a buy rating last month
Copying Leonid Timashev's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +43.91% per trade.
2 Years
xxx
Success Rate
32/32 ratings generated profit
Average Return
+84.91%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +84.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AXSM Analyst Recommendation Trends
Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
26
14
2
1
0
Buy
17
14
22
26
32
Hold
1
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
28
24
27
33
Each month's total comprises the sum of three months' worth of ratings.
AXSM Financial Forecast
AXSM Stock Forecast FAQ
What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 196.82.
What is AXSM’s upside potential, based on the analysts’ average price target?
Axsome Therapeutics Inc has 17.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AXSM a Buy, Sell or Hold?
Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
What is Axsome Therapeutics Inc’s price target?
The average price target for Axsome Therapeutics Inc is 196.82. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $248.00 ,the lowest forecast is $148.00. The average price target represents 17.47% Increase from the current price of $167.55.
The highest analyst price target is $248.00 ,the lowest forecast is $148.00. The average price target represents 17.47% Increase from the current price of $167.55.
What do analysts say about Axsome Therapeutics Inc?
Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of AXSM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.